| human | Q5 |
| P496 | ORCID iD | 0000-0002-7852-9137 |
| P1153 | Scopus author ID | 7102929864 |
| P69 | educated at | Biblioteca del Dipartimento di biologia evolutiva e comparata. Università degli studi di Napoli Federico II | Q113169497 |
| P108 | employer | University of Campania "Luigi Vanvitelli" | Q3551649 |
| P734 | family name | Valentini | Q28800578 |
| Valentini | Q28800578 | ||
| Valentini | Q28800578 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q54164380 | 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. |
| Q34375158 | 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative |
| Q39955870 | A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis |
| Q61628565 | ANTINUCLEAR ANTIBODIES IN FIRST-DEGREE RELATIVES OF PATIENTS WITH POLYMYOSITIS-DERMATOMYOSITIS: ANALYSIS OF THE RELATIONSHIP WITH HLA HAPLOTYPES |
| Q39748097 | Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients |
| Q36208563 | Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers |
| Q60924682 | Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association |
| Q35802808 | Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin |
| Q61628536 | Anti-inflammatory New trends in the treatment of the patient with systemic sclerosis |
| Q46452306 | Apolipoprotein A-I-dependent cholesterol esterification in patients with rheumatoid arthritis |
| Q51652950 | Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis: analysis of relationships with epidemiologic and clinical parameters. |
| Q54511770 | Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis. |
| Q57612985 | Association of a KCNA5 gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population |
| Q54421707 | Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population. |
| Q43049357 | Asthenoazoospermia in patients receiving anti-tumour necrosis factor {alpha} agents. |
| Q34684413 | Autoantibodies recognizing the amino terminal 1-17 segment of CENP-A display unique specificities in systemic sclerosis |
| Q47967636 | Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. |
| Q57612857 | Brief Report: Candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity |
| Q44425363 | Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study |
| Q51452981 | CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc). |
| Q61628561 | Cardiac Involvement in Rheumatoid Arthritis: An Echocardiographic Study |
| Q47615498 | Cardiac involvement in undifferentiated connective tissue disease at risk for systemic sclerosis (otherwise referred to as very early-early systemic sclerosis): a TDI study. |
| Q56974596 | Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database |
| Q54469768 | Cell-free DNA in the plasma of patients with systemic sclerosis. |
| Q43730907 | Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. |
| Q40697273 | Classification of systemic sclerosis. |
| Q42983684 | Clinical and subclinical atherosclerosis in systemic sclerosis: consequences of previous corticosteroid treatment. |
| Q37690559 | Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis |
| Q41108942 | Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis |
| Q61628572 | Colc hicine treatment of Behqet's disease in children |
| Q61628520 | Comment on ‘Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?’ |
| Q61628533 | Comment on: Disease Activity Criteria in Scleroderma |
| Q36677277 | Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions |
| Q42963326 | Cyclophosphamide in systemic sclerosis: still in search of a 'real life' scenario |
| Q45226627 | EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research |
| Q60641609 | Early Systemic Sclerosis: Analysis of the Disease Course in Patients With Marker Autoantibody and/or Capillaroscopic Positivity |
| Q60641610 | Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels |
| Q46106790 | Early onset neutropenia after mycophenolate mofetil in systemic sclerosis |
| Q39938323 | Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features |
| Q33766384 | Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers |
| Q36633414 | Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement |
| Q61628549 | Echocardiographic alterations in systemic sclerosis: A longitudinal study |
| Q35638615 | Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects |
| Q35550528 | European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. |
| Q35550511 | European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. |
| Q61628555 | Foot involvement in systemic sclerosis: A longitudinal study of 100 patients |
| Q21144954 | Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis |
| Q48058216 | Glucocorticoids in systemic sclerosis: patients' beliefs and treatment adherence |
| Q61628582 | Griseofulvin for eosinophilic fasciitis |
| Q44855486 | HLA-SD antigens in progressive systemic sclerosis |
| Q34066564 | High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis |
| Q51491387 | High prevalence of metabolic syndrome in patients with ankylosing spondylitis. |
| Q53201202 | High prevalence of subclinical cardiovascular abnormalities in patients with systemic lupus erythematosus in spite of a very low clinical damage index. |
| Q61628566 | Human Basophil Releasability. VIII. Increased Basophil Releasability in Patients with Scleroderma |
| Q52911127 | IL-22 capacitates dermal fibroblast responses to TNF in scleroderma. |
| Q61628528 | Impaired exercise performance in systemic sclerosis and its clinical correlations |
| Q46441368 | Inappropriate exercise-induced increase in pulmonary artery pressure in patients with systemic sclerosis. |
| Q61628558 | Increased Expression of CD40 Ligand in Activated CD4+T Lymphocytes of Systemic Sclerosis Patients |
| Q61628573 | Influence of Testosterone Therapy on Clinical and Immunological Features of Autoimmune Diseases Associated with Klinefelter’s Syndrome |
| Q61628540 | Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis |
| Q35784089 | Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise |
| Q40725518 | Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study |
| Q47318191 | Low-dose intravenous cyclophosphamide in systemic sclerosis: a preliminary safety study |
| Q46934931 | Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. |
| Q34486262 | Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study |
| Q51693090 | Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders. |
| Q61628567 | Lymphocyte proliferative response to mitogenic monoclonal antibodies in systemic sclerosis. Evidence for unresponsiveness to murine monoclonal antibodies of IgG1 isotype |
| Q56966479 | Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in t |
| Q38488536 | New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis |
| Q37609999 | Non-Hodgkin's lymphoma in systemic sclerosis: case and literature review |
| Q39762874 | Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis |
| Q45715684 | Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: is T-cell response aimed to play a protective role? |
| Q61628541 | Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin |
| Q35954658 | Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency |
| Q61628539 | Preclinical and prognostically relevant cardiovascular disease burden in systemic lupus erythematosus with low clinical damage index |
| Q61628574 | Pregnancy and systemic sclerosis |
| Q61628580 | Presence of eosinophilia in progressive systemic sclerosis and localized scleroderma |
| Q38163917 | Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries |
| Q56452346 | Prevalence of anti-toxoplasma antibodies in patients with autoimmune diseases |
| Q48030157 | Prevalence of hepatitis C serum antibody in autoimmune diseases |
| Q61628557 | Proximal stomach function in systemic sclerosis: relationship with autonomic nerve function |
| Q36687460 | Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease |
| Q61628577 | Relapsing polychondritis with aortic arch aneurysm and aortic arch syndrome |
| Q92678438 | Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual |
| Q48617946 | Right atrial morphology and function in patients with systemic sclerosis compared to healthy controls: a two-dimensional strain study. |
| Q61628544 | Scleroderma Subsetting |
| Q47677729 | Serologic profile and mortality rates of scleroderma renal crisis in Italy |
| Q51550147 | Serum CXCL4 increase in primary Sjögren's syndrome characterizes patients with microvascular involvement and reduced salivary gland infiltration and lymph node involvement. |
| Q61628523 | Skin Manifestations of Systemic Sclerosis |
| Q46377829 | Stress Doppler echocardiography in systemic sclerosis: evidence for a role in the prediction of pulmonary hypertension |
| Q36060142 | Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease |
| Q61628550 | Successful neridronate therapy in transient osteoporosis of the hip |
| Q34163475 | Systemic sclerosis |
| Q61628553 | Systemic sclerosis could mask the presentation of psoriasis in a patient with symptomatic and bilateral sacroiliitis |
| Q38245569 | Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature |
| Q34559161 | Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients |
| Q61628579 | TEMPORAL ARTERY BIOPSY |
| Q57753621 | The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis |
| Q97568064 | The Challenge of Very Early Systemic Sclerosis |
| Q40404296 | The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index |
| Q61628551 | The arthropathy of systemic sclerosis: a 12 month prospective clinical and imaging study |
| Q35556371 | The assessment of the patient with systemic sclerosis |
| Q61628531 | The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy |
| Q61628564 | The complement system and systemic sclerosis |
| Q40099352 | The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis |
| Q33632892 | The immunodominant epitope of centromere-associated protein A displays homology with the transcription factor forkhead box E3 (FOXE3). |
| Q57998663 | The origin of tendon friction rubs in patients with systemic sclerosis: A sonographic explanation |
| Q44015237 | The role of infections in the immunopathogensis of systemic sclerosis--evidence from serological studies |
| Q45364555 | Tissue Doppler imaging in systemic sclerosis: a 3-year longitudinal study |
| Q44375660 | Type-1 response in peripheral CD4+ and CD8+ T cells from patients with Hashimoto's thyroiditis. |
| Q38280843 | Undifferentiated Connective Tissue Disease at risk for systemic sclerosis (SSc) (so far referred to as very early/early SSc or pre-SSc). |
| Q38784389 | Update of EULAR recommendations for the treatment of systemic sclerosis |
| Q43724280 | Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database |
| Q92481417 | Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study |
| Q42111569 | What does the clinician need to improve patient care in systemic sclerosis? |
| Q38364657 | Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? |
| Q61628525 | “To Be or Not To Be,” Ten Years After: Evidence for Mixed Connective Tissue Disease as a Distinct Entity |
| Q57807781 | −238 and +489 TNF-α along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis |
Search more.